Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.
More info
itaeng
Home
30 Nov 2009
Irritable Bowel Syndrome - OBIS Study. Otilonium Bromide maintains its efficacy even after treatment
Otilonium bromide, a drug used in the treatment of irritable bowel syndrome, maintains its efficacy up to 10 weeks following administration. The results of the international study OBIS (Otilonium Bromide in Irritable Bow...
Read more
01 Nov 2009
www.mimosa-study.com
Mimosa Project in collaboration with ANT against ovarian cancer http://www.mimosa-study.com
Read more
20 Oct 2009
Menarini is granted European rights to Adenuric®, innovative drug for chronic hyperuricaemia in gout.
Ipsen and Menarini announced today the signature of an agreement under which Ipsen, an innovation-driven international specialty pharmaceutical group, grants Menarini exclusive rights for 41 countries for Adenuric® (febuxosta...
Read more

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more